Literature DB >> 3211553

Screening for glaucomatous visual field defects: the relationship between sensitivity, specificity and the number of test locations.

D B Henson1, B C Chauhan, A Hobley.   

Abstract

The visual field results from 104 eyes with early glaucomatous loss and 1860 normal eyes have been used to derive the relationship between sensitivity, specificity and the number of test locations in a visual field screening test. A logarithmic relationship was found between sensitivity and the number of test locations and a linear relationship between specificity and the number of test locations. The results indicate that large numbers of test locations are not required to reach high levels of sensitivity and that clinically it might be better to screen all patients with a few stimuli quickly than to examine carefully those patients who meet a precondition such as raised intraocular pressure or abnormal disc appearance.

Entities:  

Mesh:

Year:  1988        PMID: 3211553     DOI: 10.1111/j.1475-1313.1988.tb01027.x

Source DB:  PubMed          Journal:  Ophthalmic Physiol Opt        ISSN: 0275-5408            Impact factor:   3.117


  3 in total

1.  Performance of the 24-2-5 frequency doubling technology screening test: a prospective case study.

Authors:  P G D Spry; H M Hussin; J M Sparrow
Journal:  Br J Ophthalmol       Date:  2007-03-27       Impact factor: 4.638

2.  Predicting progressive glaucomatous optic neuropathy using baseline standard automated perimetry data.

Authors:  Shaban Demirel; Brad Fortune; Juanjuan Fan; Richard A Levine; Rodrigo Torres; Hau Nguyen; Steven L Mansberger; Stuart K Gardiner; George A Cioffi; Chris A Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-20       Impact factor: 4.799

Review 3.  The value of visual field testing in the era of advanced imaging: clinical and psychophysical perspectives.

Authors:  Jack Phu; Sieu K Khuu; Michael Yapp; Nagi Assaad; Michael P Hennessy; Michael Kalloniatis
Journal:  Clin Exp Optom       Date:  2017-06-22       Impact factor: 2.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.